Schulthess Klinik Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2012
NCT01144000
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Miriam Marks | Schulthess Klinik

Active Ingredients

Drugs in Phase 2 Trials (1)

daptomycin (cubicin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Infections (Phase 2)

Staphylococcal Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1